• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Fueling the Drug Discovery Engine: Biotech Investment and Business Trends

Posted on: Thursday, 21 August 2008, 06:01 CDT

Research and Markets (http://www.researchandmarkets.com/research/30e8bd/fueling_the_drug_d) has announced the addition of Decision Resources, Inc.'s new report "Fueling the Drug Discovery Engine: Biotech Investment and Business Trends" to their offering.

Promising new therapies and drug discovery approaches are within reach, but the pharmaceutical and biotechnology industries face unprecedented scientific, business, and regulatory challenges. Can the two industries develop and exploit a mutually beneficial synergy to ensure the long-term prosperity of both? A range of strategic choices offers positive answers.

This report includes a unique and detailed analysis of new molecular entities (NMEs) approved by the FDA from 2000 to 2007. In this study, we identify which of these NMEs operate through novel mechanisms of action. Our analysis provides unique insight into the pharmaceutical and biotechnology industries' level of innovation in drug discovery.

Get the Answers You Need to Shape Your Strategy:

-- Promising new therapies and drug discovery approaches are on the horizon, but drug developers face unprecedented challenges in a changing drug discovery landscape. What challenges confront both the pharmaceutical and biotechnology industries? What challenges are particular to each industry? What strategic choices are companies making today to advance drug discovery and ensure their long-term prosperity?

-- In 2007, corporate partnerships between biotech and pharmaceutical companies for platform technologies surged. What factors account for pharmaceutical companies' renewed interest in platform technologies? Which technologies have attracted the greatest interest, and why? Which companies were involved in 2007's highest-value partnerships? How will these alliances advance drug discovery and innovation?

-- M&As among pharmaceutical, biotechnology, and related life science companies have surged from 110 deals in 2002 to 315 deals in 2007. Which pharmaceutical companies completed the highest-value biotech acquisitions in 2007? What will they gain? Do the same motives drive biotech companies' M&As? What does it mean to call M&A "the new IPO"?

-- Private and public financing is the engine that drives biotechnology companies--most cannot sustain themselves without it. How do investors influence the direction of the biotech industry? What is the most important factor in large investment decisions? What do the largest venture capital deals of 2007 reveal about trends in drug discovery financing?

-- Industry critics charge that pharmaceutical companies are lacking in innovation, but the industry has launched many innovative drugs in recent years. Which recently launched new molecular entities (NMES) operate on novel targets or through new mechanisms of action? How have these drugs performed in the marketplace? What are the benefits and risks of developing first-in-class novel NMEs?

Scope:

-- Corporate partnerships: within and across pharma and biotech industries; high-value partnerships, 2007 and 2008; lead identification, development, optimization; target identification, validation; therapeutic and discovery platforms; biomarkers.

-- Mergers & acquisitions: M&A surge in 2007; high-value pharmaceutical M&As pipeline-driven, high-value biotechnology M&As M&A as the "new IPO."

-- Biotechnology financing: venture capital; large VC investments; Series A and seed financings; IPOs.

-- Drug discovery innovation: pharmaceutical industry under fire; NMEs approved, 2000-2007; novel approaches to cardiovascular disease, diabetes, other diseases; sales of new drugs.

-- Outlook: investor influence in biotechnology; M&As: aligning interests; evolving business models.

Key Topics Covered: Executive Summary Strategic Considerations Introduction Corporate Partnerships Lead Identification Therapeutic Platforms Discovery Platforms Lead Development Partnering Strategy in Lead Identification and Development Target Identification and Target Validation Biomarkers Lead Optimization Mergers & Acquisitions Pharmaceutical Mergers & Acquisitions Biotechnology Mergers & Acquisitions M&A: The New IPO . Biotechnology Financing Venture Capital Large VC Investments Series A and Seed Financings Initial Public Offerings Drug Discovery Innovation Outlook Investor Influence in Biotech M&A: Aligning Interests Evolving Industries

For more information visit http://www.researchandmarkets.com/research/30e8bd/fueling_the_drug_d

Source: Business Wire

More News in this Category